[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100382658":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":17,"locations":23,"responsibleParty":48,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":7,"maxAge":7,"enrollmentInfo":64,"targetDuration":67,"studyType":68,"phases":7,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Central Hospital, Nancy, France","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Rivaroxaban","Rivaroxaban 10 mg or 15 mg or 20 mg OD Dabigatran 110 mg or 150 mg BID Apixaban 2.5 mg or 5 mg or 10 mg BID",[14,15,16],"Dabigatran","Apixaban","Edoxaban",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Virginie Dufrost, MD, MSc","CONTACT","+33383157828","v.dufrost@chru-nancy.Fr",[24],{"facility":25,"status":26,"city":27,"state":7,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Stéphane Zuily","RECRUITING","Nancy","54500","France","FR",{"type":32,"coordinates":33},"Point",[34,35],6.18496,48.68439,{"lat":35,"lon":34},[38,42,44,47],{"name":39,"role":20,"phone":40,"phoneExt":7,"email":41},"Stéphane Zuily, MD, PhD","+33383157354","s.zuily@chru-nancy.fr",{"name":19,"role":43,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"name":45,"role":46,"phone":7,"phoneExt":7,"email":7},"Denis Wahl, MD, PhD","SUB_INVESTIGATOR",{"name":39,"role":46,"phone":7,"phoneExt":7,"email":7},{"type":49,"investigatorFullName":25,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Professor",[52],{"name":53,"class":54},"International Society on Thrombosis and Haemostasis","UNKNOWN","100382658","international-registry-of-thrombotic-aps-patients-treated-with-direct-oral-anticoagulants-100382658",false,"NCT04262492","International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants","OBServaToire INternational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs","OBSTINATE","Inclusion Criteria:\n\n* Patient receiving a comprehensive information about the study, and not opposed to participate\n* Age ≥ 18 yo\n* Classification of definite APS according to revised Sapporo-Sydney criteria\n* Direct oral anticoagulant treatment prescribed during at least 6 months or with the possibility of follow-up of at least 6 months\n\nExclusion Criteria:\n\n* Incomplete revised Sapporo-Sydney criteria\n* No data regarding the recurrent thrombosis\n* Pregnant woman\n* Age \\\u003C 18 yo","ALL",{"count":65,"type":66},500,"ESTIMATED","5 Years","OBSERVATIONAL","This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.",[71,72,73],"Antiphospholipid Syndrome","Thrombosis","Anticoagulants Causing Adverse Effects in Therapeutic Use",[75,76],"antiphospholipid syndrome","direct oral anticoagulants","2026-05-07",{"date":79,"type":80},"2026-05-08","ACTUAL",{"date":82,"type":80},"2020-10-21",{"date":84,"type":66},"2031-04-21",{"name":25,"class":6},1]